Compare CNS & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNS | GH |
|---|---|---|
| Founded | 1986 | 2011 |
| Country | United States | United States |
| Employees | N/A | 2021 |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 13.2B |
| IPO Year | 2004 | 2018 |
| Metric | CNS | GH |
|---|---|---|
| Price | $66.52 | $112.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 21 |
| Target Price | $72.50 | ★ $99.48 |
| AVG Volume (30 Days) | 287.7K | ★ 1.8M |
| Earning Date | 01-21-2026 | 02-19-2026 |
| Dividend Yield | ★ 3.83% | N/A |
| EPS Growth | ★ 18.87 | N/A |
| EPS | ★ 3.19 | N/A |
| Revenue | $552,096,000.00 | ★ $902,569,000.00 |
| Revenue This Year | $8.24 | $35.00 |
| Revenue Next Year | $9.40 | $26.80 |
| P/E Ratio | $20.32 | ★ N/A |
| Revenue Growth | 11.13 | ★ 30.38 |
| 52 Week Low | $58.39 | $33.75 |
| 52 Week High | $93.19 | $112.43 |
| Indicator | CNS | GH |
|---|---|---|
| Relative Strength Index (RSI) | 65.26 | 70.14 |
| Support Level | $62.43 | $97.31 |
| Resistance Level | $64.82 | $104.75 |
| Average True Range (ATR) | 1.34 | 3.83 |
| MACD | 0.42 | 0.26 |
| Stochastic Oscillator | 95.59 | 99.25 |
Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for around two thirds of its $90.9 billion in managed assets at the end of September 2025. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 39% (26%) of its managed assets (base management fees) from institutional clients, 48% (54%) from open-end funds, and 13% (20%) from closed-end funds.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.